Clinical trials
HSCT clinical trials
Below are recruiting hsct clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06082947Recruiting
Stem cell transplant with special cell depletion for children and young adults
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
Columbus, OhioAges Up to 30 years - NCT06111612Recruiting
Intensive chemo before stem cell transplant for myeloid cancers with spread outside marrow
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06111625RecruitingPhase 2
Short blinatumomab before stem cell transplant for low B-ALL
This trial tests a short course of blinatumomab (a targeted immunotherapy) given before a stem cell transplant in people with low amounts of B-ALL leukemia. The goal is to prepare the body for transplant and improve outcomes.
Chengdu, SichuanAges 16–65 - NCT06125483Recruiting
Cord blood transplant for cancer relapse after stem cell transplant
This trial tests a second transplant using cord blood after a first stem cell transplant failed to keep the cancer away. It's for people with blood cancers like leukemia that have come back.
Suzhou, JiangsuAges 10–65 - NCT06130579RecruitingPhase 2
Interferon-α for TP53-mutated blood cancer after transplant
This trial tests whether a medicine called interferon-α can help people with a specific gene mutation (TP53) in their blood cancer after they've had a donor stem cell transplant. It aims to prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 12–65 - NCT06155188Recruiting
New transplant method for childhood leukemia
This study tests a new combination of medicines to help donor cord blood cells grow better in children with leukemia after a transplant.
Guangzhou, GuangdongAges 1 month–18 years - NCT06198517Recruiting
Moxibustion to prevent bladder bleeding after stem cell transplant
This trial tests whether a gentle heat therapy called moxibustion (burning a special herb near the skin) can prevent bleeding in the bladder, a common side effect after stem cell transplants. It's for people getting a strong chemotherapy regimen before their transplant.
Zhengzhou, HenanAges 14–60 - NCT06198842RecruitingPhase 2
Low-dose treosulfan with PTCy for Nijmegen Breakage Syndrome transplant
This trial tests a low-dose chemotherapy regimen (treosulfan) combined with a drug called PTCy to prepare children with Nijmegen Breakage Syndrome for a stem cell transplant. The goal is to reduce side effects while helping the donor cells take hold safely.
MoscowAges 3 months–21 years - NCT06202625RecruitingPhase 2/Phase 3
Avatrombopag for low platelets after stem cell transplant
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
Beijing, Beijing MunicipalityAges 18–65 - NCT06211166Recruiting
Tracking cancer genes after stem cell transplant with digital PCR
This trial uses a precise blood test called digital PCR to measure tiny amounts of leftover cancer cells in patients who have had a stem cell transplant. It helps doctors see how well the transplant is working and if more treatment is needed.
Beijing, Beijing MunicipalityAges Any age - NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06241274Recruiting
Moxibustion for bladder bleeding after stem cell transplant
This study tests whether moxibustion (a traditional heat therapy) can help manage bladder bleeding that occurs after a donor stem cell transplant. If you have this condition, the trial aims to see if this gentle treatment can reduce symptoms.
Wuhan, HubeiAges 18–55 - NCT06301425Recruiting
Transplant study for high-risk AML based on MRD response
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
BeijingAges 16–65 - NCT06316427RecruitingPhase 1/Phase 2
CD7 CAR-T therapy for T-cell cancers that returned
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
Beijing, Beijing MunicipalityAges 1–70 - NCT06326021RecruitingPhase 1
CD33 CAR T for relapsed or refractory AML
This trial tests a new type of immune therapy called CAR T cells that target the CD33 protein on leukemia cells. It is for people with AML that has returned or not gone away after standard treatments, and who have a stem cell donor available for a transplant afterward.
Shanghai, Shanghai MunicipalityAges 1–70 - NCT06343090Recruiting
Comparing two CAR T cell treatments for children and adults with B-ALL
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
Beijing, Beijing MunicipalityAges 1–70 - NCT06393985RecruitingPhase 2
Maintenance therapy after stem cell transplant for B-ALL
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
Suzhou, JiangsuAges 18–65 - NCT06423131Recruiting
Comparing two types of stem cell transplants for children
This study compares a newer type of stem cell transplant (using special cells) to the standard method for children who need a half-matched donor. It aims to see if the new approach is safer and works as well.
Shanghai, Shanghai MunicipalityAges 2 months–18 years - NCT06458244Recruiting
Stem cell transplant for high-risk CBF-AML
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Duarte, CaliforniaAges 18 years+ - NCT06468267RecruitingPhase 2
Lower-intensity transplant with thiotepa combo for relapsed T-cell lymphoma
This study tests a stronger but safer chemo preparation before a stem cell transplant for people with T-cell lymphoma that has returned or not responded to treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06483906RecruitingPhase 2
Study of a drug combo and stem cell transplant for high-risk AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT05027945RecruitingPhase 2
Stem cell transplant for people with VEXAS syndrome
This Phase 2 trial tests whether an allogeneic stem cell transplant (from a donor) can treat VEXAS syndrome. It may help calm the body’s overactive inflammation and improve symptoms in eligible adults.
Bethesda, MarylandAges 18–75 - NCT06554197Recruiting
CMV and EBV immune testing in half-matched stem cell transplant
This trial is for patients with blood disorders who are getting a half-matched stem cell transplant (from a family donor). It tests a new way to measure your immune system's response to two common viruses (CMV and EBV) after transplant, which may help doctors prevent or treat infections better.
Suzhou, JiangsuAges 16–60
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hsct?
- Yes. Clin2 currently lists 155 recruiting hsct studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hsct trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hsct trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.